{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-dyspnoea/prescribing-information/opioids/","result":{"pageContext":{"chapter":{"id":"25b01dc5-45e8-563d-872f-cfec63e33029","slug":"opioids","fullItemName":"Opioids","depth":2,"htmlHeader":"<!-- begin field b1c8f124-56f1-4517-96fd-fcfc7e888cc7 --><h2>Opioids</h2><!-- end field b1c8f124-56f1-4517-96fd-fcfc7e888cc7 -->","summary":"","htmlStringContent":"<!-- begin item 7e6453ec-6540-4c3c-923f-bb1b48c6cbd8 --><!-- end item 7e6453ec-6540-4c3c-923f-bb1b48c6cbd8 -->","topic":{"id":"20d4363b-caf3-55a9-beed-09266efa45f4","topicId":"73af552e-909d-456c-86d1-11f7a65040d8","topicName":"Palliative care - dyspnoea","slug":"palliative-care-dyspnoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"0614f3a6-7238-5427-b059-9195b0cc2aa1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738e7584-0909-59c3-bd54-43100aed01fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ea721a0d-cda2-5620-8e3f-61e76920b9b3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"83260a2e-73f3-5abd-b049-c307d85d2cff","slug":"changes","fullItemName":"Changes"},{"id":"460710fb-be39-5a74-8adf-44beac90510f","slug":"update","fullItemName":"Update"}]},{"id":"a2422ca0-3b24-5c6e-81d8-07d257fdd44a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2753bf62-a22c-5fb2-936c-554ef07426d4","slug":"goals","fullItemName":"Goals"},{"id":"65f25469-16d4-5c7f-b7bc-a6698ca61164","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"52a827c5-48de-5c0c-8dce-6c7eeeab720d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"cd3e39be-06ce-5750-a1f7-cbc06bb58756","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"50c51a08-6607-5699-96a8-d66cb532d2c5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"05dc5599-43b4-5340-841b-3b3208f4b947","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1fd04fd1-0023-5c48-9785-d9a54c7e2eb0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a84982b-be4e-5901-a577-110f09001119","slug":"definition","fullItemName":"Definition"},{"id":"dab82422-38f4-5a30-b0db-ad2cbf33c2ab","slug":"prevalence-of-dyspnoea-in-palliative-care","fullItemName":"Prevalence of dyspnoea in palliative care"},{"id":"ea086054-ae8f-5666-9159-99b04676d230","slug":"causes-of-dyspnoea","fullItemName":"Causes of dyspnoea"},{"id":"c2601cd4-69b1-563f-870a-8110f4c24103","slug":"complications-of-dyspnoea","fullItemName":"Complications of dyspnoea"}]},{"id":"db288340-b73c-59b1-a8ba-4baec577b887","fullItemName":"Management","slug":"management","subChapters":[{"id":"62ed0387-08f9-5656-8079-a5fffee537f4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"cdb4ccb3-9b96-5651-9950-6e2e0b8f4da0","slug":"symptomatic-treatment","fullItemName":"Scenario: Symptomatic treatment"},{"id":"5b9d65e3-1fc3-558d-a95e-5e4ff147c7d7","slug":"known-cause-of-dyspnoea","fullItemName":"Scenario: Known cause of dyspnoea"},{"id":"3b6b57e5-ba14-5311-bbf3-d996401c7dc6","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"},{"id":"9983f052-047c-5346-adfc-b741909ce269","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"08f118cb-d39f-532d-b39f-fa97739c656d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"22221f0a-e6f8-5976-bf6c-1024268816e0","slug":"oxygen","fullItemName":"Oxygen"},{"id":"25b01dc5-45e8-563d-872f-cfec63e33029","slug":"opioids","fullItemName":"Opioids"},{"id":"b7f561a2-0802-545a-b7d1-db218387a6e5","slug":"benzodiazepines","fullItemName":"Benzodiazepines"}]},{"id":"9f0bdd3b-82e3-5cbb-908f-d36a887457a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5c3c7cfe-04b9-5ac4-9255-be56a20c7b5c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3aa322d7-2279-512c-93a7-55426d21da21","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b889ecee-814d-5e79-b596-a024fbee0acf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7e27fb69-52fd-5ddc-8f84-6164bb8615d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c1800f44-6de2-534a-a4ff-32b8b5cf6e24","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6b7633c0-45a5-5a2e-b564-f185c2b9ef5f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2d28faa0-4a5f-565b-a431-6339d01f6e91","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"08f118cb-d39f-532d-b39f-fa97739c656d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a9c31b8a-cb5c-5400-98ab-a972cc430428","slug":"choice-of-opioid","fullItemName":"Choice of opioid","depth":3,"htmlHeader":"<!-- begin field a37099dd-b359-4954-8b1f-a025a5be5238 --><h3>Choice of opioid</h3><!-- end field a37099dd-b359-4954-8b1f-a025a5be5238 -->","summary":"","htmlStringContent":"<!-- begin item c89c10e7-a9bc-4ec9-bb85-7c2bbbbc208d --><!-- begin field 9c698b4b-8e03-425b-977c-ecec632dbc90 --><ul><li>Immediate-release oral morphine is the usual opioid of choice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">NHS Lothian, 2010</a>].</li><li>If the person cannot take oral medication, use morphine or diamorphine as a subcutaneous bolus when required, or a subcutaneous continuous infusion delivered through a syringe driver [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">NHS Scotland, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">NHS Lothian, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Twycross, 2014</a>].<ul><li>Diamorphine is much more soluble than morphine and therefore easier to administer in higher doses. It is also compatible with most other drugs which may need to be administered by a subcutaneous infusion. However, morphine is an alternative and most people do not require doses large enough to cause solubility issues [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Twycross, 2014</a>].</li></ul></li><li>Opioids are most helpful at relieving breathlessness at rest, particularly in the last days of life. They are less effective at reducing breathlessness on exertion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Wilcock, Personal Communication, 2012</a>].</li></ul><!-- end field 9c698b4b-8e03-425b-977c-ecec632dbc90 --><!-- end item c89c10e7-a9bc-4ec9-bb85-7c2bbbbc208d -->","subChapters":[]},{"id":"12318d30-8ef0-5b77-80ec-63c3caf4c40c","slug":"oral-morphine-dose-regimen","fullItemName":"Oral morphine dose regimen","depth":3,"htmlHeader":"<!-- begin field dafa039f-ac9d-4a91-b3a3-7a34289df389 --><h3>Oral morphine dose regimen</h3><!-- end field dafa039f-ac9d-4a91-b3a3-7a34289df389 -->","summary":"","htmlStringContent":"<!-- begin item 3458386f-c803-4b3b-bb9c-6903c628d8be --><!-- begin field 6bec6757-c780-4cb8-a42a-dbd437cb019b --><ul><li><strong>Local guidelines should be followed if available, as there is a wide variation in regimens used in clinical practice.</strong><ul><li>In the absence of local guidelines CKS cannot be prescriptive, but can only offer a general guide based on UK guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">NHS Lothian, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Northern England Clinical Networks, 2016</a>], the Palliative Care Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Twycross, 2014</a>], and on the professional opinion of an expert reviewer of this CKS topic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Wilcock, Personal Communication, 2012</a>].</li><li>An opioid dose regimen should always be tailored to an individual's needs and requirements. If a clinician is still unsure how best to manage a person in this scenario, they should seek specialist advice.</li></ul></li><li>The initial starting dose will depend on the person's previous exposure to opioids (as well as other factors such as the age of the person, degree of frailty, associated morbidity such as chronic obstructive pulmonary disease or interstitial lung disease, and renal and liver function). In people with dyspnoea, morphine should be increased more cautiously than when used for palliative care pain relief.</li><li><strong>In an opioid-naive person:</strong><ul><li>Start with oral morphine 2 mg or 2.5 mg.</li><li>Most people can take this dose every 4 hours and as required, although people with breathlessness may not need as frequent dosing (for example people with dyspnoea on exertion can just take the morphine dose when required as long as they plan their activity, and take the morphine dose about 30 minutes in advance).</li></ul></li><li><strong>In a person taking a weak opioid </strong>(for example codeine):<ul><li>Start an oral morphine dosage of 2.5–5 mg (depending on the person's circumstances, comorbidities, and other medication) every 4 hours and as required. Only continue the weak opioid if appropriate.</li><li>As previously, if people with dyspnoea on exertion plan their activity, they may take the morphine dose just 'as required'.</li></ul></li><li><strong>In a person already receiving regular (analgesic) morphine:</strong><ul><li>Increase the regular dose of morphine by about one third every 2 to 3 days until symptoms are controlled or adverse effects prevent further dose increases.</li></ul></li><li><strong>Titrating the dose</strong><ul><li>If, after a clinical assessment, the person has no adverse effects and the morphine is demonstrating some benefit, reassess the morphine dose and increase if necessary, taking into account factors such as the age of the person, degree of frailty, associated morbidity, and renal and liver function.</li><li>Repeat this process every 2 days until breathlessness is controlled (that is the person is comfortable at rest and able to sleep without frequent waking because of breathlessness) at a dose which is tolerated.</li><li>Once a stable dose has been reached, the new 4-hourly and 'as required' dose is one tenth to one sixth of the new total daily dose (unless a person with dyspnoea on exertion is controlled on an 'as required' dose as explained previously).</li></ul></li><li><strong>Choice of oral morphine formulation</strong><ul><li>If the person needs regular morphine dosing throughout the day for dyspnoea, convert to once- or twice-daily administration of modified-release morphine. However, if only one or two doses are needed each day to control symptoms, then it may be fine to continue with 'as required' doses of standard release morphine.</li></ul></li></ul><!-- end field 6bec6757-c780-4cb8-a42a-dbd437cb019b --><!-- end item 3458386f-c803-4b3b-bb9c-6903c628d8be -->","subChapters":[]},{"id":"02f954f1-ea4e-515a-9905-0b048e9e4499","slug":"subcutaneous-opioid-dose-regimen","fullItemName":"Subcutaneous opioid dose regimen","depth":3,"htmlHeader":"<!-- begin field 80cb3006-1796-492a-956d-08d54959d778 --><h3>Subcutaneous opioid dose regimen</h3><!-- end field 80cb3006-1796-492a-956d-08d54959d778 -->","summary":"","htmlStringContent":"<!-- begin item f13742ed-ad8f-498a-bb89-5aa2a717ed87 --><!-- begin field 31ac3a41-d487-4ed7-aa3f-4e78edb91048 --><ul><li><strong>Local guidelines should be followed if available, as there is a wide variation in regimens used in clinical practice.</strong><ul><li>In the absence of local guidelines CKS cannot be prescriptive, but can only offer a general guide based on UK guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">NHS Lothian, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Northern England Clinical Networks, 2016</a>], the Palliative Care Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Twycross, 2014</a>] and on the professional opinion of an expert reviewer of this CKS topic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Wilcock, Personal Communication, 2012</a>].</li><li>An opioid dose regimen should always be tailored to an individual's needs and requirements. If a clinician is still unsure how best to manage a person in this scenario, they should seek specialist advice.</li></ul></li><li><strong>Subcutaneous morphine in an opioid-naive person:</strong><ul><li>Start with a one-off dose of 1.25–2.5 mg and then give as required (up to hourly).</li><li>Prescribe morphine 10 mg/24 hours by continuous subcutaneous infusion by syringe driver.</li><li>If one or two rescue doses are needed in 24 hours, increase the syringe driver dose by 50%.</li><li>If 3 or more rescue doses are needed in 24 hours, double the syringe driver dose and increase the rescue dose to 5 mg. Rescue doses can still be given hourly as needed.</li></ul></li><li><strong>Subcutaneous diamorphine in an opioid-naive person:</strong><ul><li>Start with a one-off dose of diamorphine 1.25–2.5 mg and then give as required (up to 2 hourly).</li><li>Prescribe diamorphine 5–10 mg/24 hours by continuous subcutaneous infusion by syringe driver.</li><li>If one or two rescue doses are needed in 24 hours, increase the syringe driver dose by 50%.</li><li>If 3 or more rescue doses are needed in 24 hours, double the syringe driver dose and increase the rescue dose to 2.5–5 mg. Rescue doses can still be given hourly as needed.</li></ul></li><li><strong>If converting from oral morphine to a subcutaneous opioid:</strong><ul><li>The oral to subcutaneous potency ratio of morphine is between 1:2 and 1:3 (that is, the subcutaneous dose is one third to one half of the oral dose). In practice, most centres divide the oral dose by two and re-titrate as necessary. See Table 6.</li><li>Parenteral diamorphine is approximately three times as potent as oral morphine, so the total daily dosage of oral morphine should be divided by three to obtain the 24-hour subcutaneous dose of diamorphine. See Table 6.</li></ul></li></ul><p><strong>Table 6</strong><strong>. </strong>Equivalent doses of oral morphine sulphate to the subcutaneous route.</p><table><thead><tr><th colspan=\"1\"><p>Oral morphine dose</p></th><th colspan=\"2\"><p>Subcutaneous infusion of opioid</p></th></tr></thead><tbody><tr><td colspan=\"1\">Morphine sulphate</td><td colspan=\"1\">Morphine sulphate (approximately half of oral morphine dose)</td><td colspan=\"1\">Diamorphine hydrochloride (one third of oral morphine dose)</td></tr><tr><td colspan=\"1\">30</td><td colspan=\"1\">15</td><td colspan=\"1\">10</td></tr><tr><td colspan=\"1\">60</td><td colspan=\"1\">30</td><td colspan=\"1\">20</td></tr><tr><td colspan=\"1\">90</td><td colspan=\"1\">45</td><td colspan=\"1\">30</td></tr><tr><td colspan=\"1\">120</td><td colspan=\"1\">60</td><td colspan=\"1\">40</td></tr><tr><td colspan=\"1\">180</td><td colspan=\"1\">90</td><td colspan=\"1\">60</td></tr><tr><td colspan=\"3\"><p><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">BNF 72, 2016</a>]</p></td></tr></tbody></table><!-- end field 31ac3a41-d487-4ed7-aa3f-4e78edb91048 --><!-- end item f13742ed-ad8f-498a-bb89-5aa2a717ed87 -->","subChapters":[]},{"id":"d5917474-560f-5f3f-a7bd-e7259127d773","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a34ad6c5-3803-4eab-ba07-a1ec3b8f60bd --><h3>Adverse effects</h3><!-- end field a34ad6c5-3803-4eab-ba07-a1ec3b8f60bd -->","summary":"","htmlStringContent":"<!-- begin item 02707f34-757a-485f-bdf8-d90a3cd79501 --><!-- begin field 4f905d42-606b-4e52-afd0-ef7e88050f7e --><ul><li><strong>Drowsiness </strong>occurs commonly at the start of treatment or after dose increases. People should be warned to avoid activities in which drowsiness may be detrimental. Most people develop tolerance to drowsiness within a few days. Persistent sedation may be resolved by dose reduction or an opioid switch [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">ABPI Medicines Compendium, 2016</a>].</li><li><strong>Constipation </strong>is a common ongoing problem, because tolerance to this adverse effect does not develop with morphine use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">ABPI Medicines Compendium, 2016</a>]:<ul><li>When using an opioid, co-prescribe a regular stimulant laxative (for example senna or bisacodyl) with a faecal softener (for example docusate or lactulose), or a laxative likely to have both properties (for example co-danthramer or co-danthrusate) to prevent opioid-induced constipation. Note that people taking dantron-containing laxatives may experience reddening of the perianal area.</li></ul></li><li><strong>Other common adverse effects </strong>of morphine (especially in elderly people) include nausea, vomiting, and unsteadiness:<ul><li>If nausea and vomiting are problematic, an anti-emetic (for example haloperidol or metoclopramide) should be prescribed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Twycross, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">BNF 72, 2016</a>]. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-nausea-vomiting/\">Palliative care - nausea and vomiting</a>.</li></ul></li><li><strong>Other adverse effects </strong>of strong opioids include dry mouth, sweating, pruritus, hallucinations, myoclonus, sleep apnoea syndrome, and bronchoconstriction.</li><li>Respiratory depression from opioids is rare, and these agents do not hasten death if appropriately titrated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">Fraser Health, 2009</a>].</li></ul><!-- end field 4f905d42-606b-4e52-afd0-ef7e88050f7e --><!-- end item 02707f34-757a-485f-bdf8-d90a3cd79501 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}